Skip to main content

Advertisement

SpringerLink
Log in

Current status of neoadjuvant immunotherapy for the treatment of gastric cancer

  • REVIEW ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Gastric cancer is one of the most prevalent malignant tumors worldwide, characterized by high incidence and mortality rates. At present, comprehensive surgical treatment has enhanced the prognosis of locally advanced gastric cancer patients significantly. However, the postoperative recurrence rate remains high, and the long-term survival for patients is sub-optimal. In recent years, immunotherapy has garnered extensive attention as an innovative approach to the treatment of gastric cancer. Indeed, multiple studies have validated its therapeutic effects in advanced gastric cancer patients, leading to its incorporation into treatment guidelines. Currently, researchers are exploring the application of immunotherapy in the neoadjuvant setting globally in order to further adjust and refine neoadjuvant immunotherapy regimens for gastric cancer. This article summarizes the research progress and controversies associated with neoadjuvant immunotherapy in gastric cancer, aiming to optimize clinical benefits for gastric cancer patients undergoing this treatment approach. The retrieval methods of this study encompassed databases such as PubMed, Google Scholar, Web of Science, clinicaltrials.gov, etc. The retrieved articles included guidelines, consensus, meta-analyses, clinical trials, and reviews related to locally advanced gastric cancer published up to January 2024.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.

    Article  CAS  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  3. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.

    Article  PubMed  Google Scholar 

  4. Bahardoust M, Kheirabadi M, Donyadideh G, Khaleghian M, Haghmoradi M, Tizmaghz A. Effect of the number of negative lymph nodes removed on the survival and recurrence rate after gastrectomy in patients with gastric cancer: a multicenter retrospective cohort study. BMC Surg. 2023;23:246.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bahardoust M, Mousavi S, Moezi ZD, Yarali M, Tayebi A, Olamaeian F, et al. Effect of metformin use on survival and recurrence rate of gastric cancer after gastrectomy in diabetic patients: a systematic review and meta-analysis of observational studies. J Gastrointest Cancer. 2023. https://doi.org/10.1007/s12029-023-00955-y.

    Article  PubMed  Google Scholar 

  6. Talebi A, Mohammadnejad A, Akbari A, Pourhoseingholi MA, Doosti H, Moghimi-Dehkordi B, et al. Survival analysis in gastric cancer: a multi-center study among Iranian patients. BMC Surg. 2020;20:152.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  8. Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

    Article  CAS  PubMed  Google Scholar 

  9. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

    Article  PubMed  Google Scholar 

  10. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081–92.

    Article  CAS  PubMed  Google Scholar 

  11. Kang Y-K, Yook JH, Park Y-K, Lee JS, Kim Y-W, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nie R, Chen F, Provencio M, Wang Y, van den Ende T, van Laarhoven HWM, et al. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. Eur J Cancer. 2023;186:211–21.

    Article  CAS  PubMed  Google Scholar 

  13. Xu C, Xie X, Kang N, Jiang H. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study. J Cancer Res Clin Oncol. 2023;149:4091–9.

    Article  CAS  PubMed  Google Scholar 

  14. Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS ONE. 2018;13: e0189294.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gubin MM, Vesely MD. Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res. 2022;28:3917–28.

    Article  CAS  PubMed  Google Scholar 

  16. Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019;27:244–56.

    Article  MathSciNet  CAS  PubMed  Google Scholar 

  17. Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400:1117–29.

    Article  CAS  PubMed  Google Scholar 

  18. Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, et al. What’s new in gastric cancer: the therapeutic implications of molecular classifications and future perspectives. Int J Mol Sci. 2018;19:2659.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4: e180013.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717–26.

    Article  CAS  PubMed  Google Scholar 

  21. Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

    Article  CAS  PubMed  Google Scholar 

  22. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–41.

    Article  PubMed  Google Scholar 

  23. Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11:1353–67.

    Article  CAS  PubMed  Google Scholar 

  24. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;S0140–6736(23):02033.

    Google Scholar 

  26. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382–99.

    Article  CAS  PubMed  Google Scholar 

  27. Bang Y-J, Ruiz EY, Van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052–60.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yin Y, Lin Y, Yang M, Lv J, Liu J, Wu K, et al. Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial. Front Oncol. 2022;12: 959295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yuan S-Q, Nie R-C, Jin Y, Liang C-C, Li Y-F, Jian R, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024. https://doi.org/10.1038/s41591-023-02721-w.

    Article  PubMed  Google Scholar 

  30. Li H, Deng J, Ge S, Zang F, Zhang L, Ren P, et al. Phase study of perioperative toripalimab in combination with flot in patients with locally advanced resectable gastric/gastroesophageal junction Gej adenocarcinoma. J Clin Oncol. 2021;39:4050.

    Article  Google Scholar 

  31. Ding X, Wang X, Li B, Wang L, Guo H, Shang L, et al. PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC). J Clin Oncol. 2023;41:364.

    Article  Google Scholar 

  32. Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan X, et al. Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2021;39:216.

    Article  Google Scholar 

  33. Jiang H, Yu X, Kong M, Ma Z, Zhou D, Wang W, et al. Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma. J Clin Oncol. 2021;39:211.

    Article  Google Scholar 

  34. Liu Y, Han G, Li H, Zhao Y, Li Z, Zhuang J, et al. Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety. J Clin Oncol. 2021;39:4036.

    Article  Google Scholar 

  35. Liu Z, Liu N, Zhou Y, Niu Z, Jiang H, Zhu Y, et al. Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy: data update. J Clin Oncol. 2022;40: e16044.

    Article  Google Scholar 

  36. Verschoor YL, van de Haarvan den Bergvan SandickKodachvan Dieren JJGJWLLJM, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat Med. 2024. https://doi.org/10.1038/s41591-024-02898-8.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sun W, Veeramachaneni N, Al-Rajabi R, Madan R, Kasi A, Al-Kasspooles M, et al. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma. Cancer Med. 2023;12:16098–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Alcindor T, Opu T, Elkrief A, Khosrow-Khavar F, Mueller CL, Cools-Lartigue J, et al. Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: preliminary results. J Clin Oncol. 2021;39:4046.

    Article  Google Scholar 

  39. Janjigian Y, Al-Batran S, Wainberg Z, Cutsem E, Molena D, Muro K, et al. LBA73 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1254–335.

    Article  Google Scholar 

  40. Shitara K, Rha S, Wyrwicz L, Oshima T, Karaseva N, Osipov M, et al. LBA74-Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study. Ann Oncol. 2023;34:S1254–335.

    Article  Google Scholar 

  41. Al-Batran SE, Lorenzen S, Thuss-Patience PC, Homann N, Schenk M, Lindig U, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40:4003.

    Article  Google Scholar 

  42. Yuan Z, Cui H, Wang S, Liang W, Cao B, Song L, et al. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1103320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, et al. Perioperative treatment in resectable gastric cancer: current perspectives and future directions. Cancers (Basel). 2019;11:399.

    Article  CAS  PubMed  Google Scholar 

  44. Levy A, Chargari C, Marabelle A, Perfettini J-L, Magné N, Deutsch E. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur J Cancer. 2016;62:36–45.

    Article  CAS  PubMed  Google Scholar 

  45. Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol. 2020;25:801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9: e002485.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y, et al. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 2022;13:6807.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wei J, Lu X, Liu Q, Fu Y, Liu S, Zhao Y, et al. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023;14:4904.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  49. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, et al. Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction. Clin Cancer Res. 2022;28:3021–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Du R, Ming J, Geng J, Sui X, Li S, Liu Z, et al. 1215P - Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: a phase II study. Ann Oncol. 2022;33:S555–80.

    Article  Google Scholar 

  51. Li S, Xu Q, Dai X, Zhang X, Huang M, Huang K, et al. Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: a meta-analysis and systematic review. J Clin Oncol. 2022;40:291.

    Article  Google Scholar 

  52. Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, et al. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer. 2022;25:619–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Janjigian Y, Ajani J, Moehler M, Garrido M, Gallardo C, Shen L, et al. LBA7-nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Ann Oncol. 2021;32:S1283–346.

    Article  Google Scholar 

  54. Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, et al. VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled Phase-2-study. Front Oncol. 2019;9:1320.

    Article  PubMed  Google Scholar 

  55. Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer. 2021;124:595–603.

    Article  CAS  PubMed  Google Scholar 

  56. Kim W-H, Gomez-Izquierdo L, Vilardell F, Chu K-M, Soucy G, Dos Santos LV, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational her-eagle study. Appl Immunohistochem Mol Morphol. 2018;26:239–45.

    Article  CAS  PubMed  Google Scholar 

  57. Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan X, et al. Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2022;40:296.

    Article  Google Scholar 

  58. Wang F, Zhao C, Xia J, Liu Z, Meng X, Shan Z, et al. Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2=positive resectable gastric gastroesophageal junction cancer (GC/EGJC): preliminary results of a phase II, single-arm trial. Ann Oncol. 2023;34:S852–86.

    Google Scholar 

  59. Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T, et al. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

    Article  CAS  PubMed  Google Scholar 

  61. Andre T, Berton D, Curigliano G, Jimenez-Rodriguez B, Ellard S, Gravina A, et al. Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study. J Clin Oncol. 2022;40:2587.

    Article  Google Scholar 

  62. André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41:255–65.

    Article  PubMed  Google Scholar 

  63. Pietrantonio F, Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol. 2023;41:358.

    Article  Google Scholar 

  64. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250–4.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  66. Chen L, Ye Z, Liu G, Lin Q, Chi Y, Wang J, et al. 85P-Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV, large Borrmann III type and Bulky N positive advanced gastric cancer: a single-arm multicenter trial (TAOS-3B-Trial). Ann Oncol. 2022;16: 100102.

    Google Scholar 

  67. Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14:8.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  68. Li C, Zheng Y, Shi Z, Yang L, Zhang B, Wang Z, et al. 1512MO-Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase III trial (DRAGON IV). Ann Oncol. 2023;34:S852–86.

    Article  Google Scholar 

  69. Duffy MJ, Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65:1228–38.

    Article  CAS  PubMed  Google Scholar 

  70. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (grant number 82260555), Medical Innovation and Development Project of Lanzhou University (grant number lzuyxcx-2022–177), and Major Science and Technology Projects of Gansu Province (grant number 22ZD6FA021-4).

Author information

Author notes

  1. Xijie Zhang, Bo Liu, and Rui Wang contributed equally to this work.

Authors and Affiliations

  1. The Second Clinical Medical School, Lanzhou University, Lanzhou, China

    Xijie Zhang, Bo Liu, Rui Wang & Wence Zhou

  2. Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China

    Xin Li & Wence Zhou

Authors
  1. Xijie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wence Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XJZ and WCZ designed and prepared the manuscript; BL and RW performed the information retrieval and summary; XJZ, BL, and RW drafted the manuscript and Tables 1 and 2; XL contributed to the revision of the manuscript; WCZ guided the manuscript writing and provided financial support. All authors read and approved the final manuscript for submission.

Corresponding author

Correspondence to Wence Zhou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest. The authors have no relevant financial or non-financial interests to disclose..

Ethical approval and informed consent

The manuscript does not contain clinical studies or patient data, so it is not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Liu, B., Wang, R. et al. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer. Clin Transl Oncol (2024). https://doi.org/10.1007/s12094-024-03437-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12094-024-03437-0

Keywords

Search

Navigation